AUM and trading activity drives Oppenheimer's wealth management business. Read why we remain bullish on OPY stock.

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

Alphabet (GOOGL) will be stepping up to the earnings plate tomorrow (February 4), when it will deliver its fourth quarter ...

Over the years, we’ve heard hundreds of time about how we have enough nuclear weapons to destroy the world. But is that ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Benny Safdie is the latest actor to join the cast of The Odyssey, the next movie from Christopher Nolan, according to The ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

British consumers’ appetite for home entertainment reached new heights in 2024, with the sector surpassing £5.1 billion ($6.4 ...

Oppenheimer downgraded Apple from "outperform" to "perform" because it is struggling to adapt to a competitive AI landscape.

Oppenheimer (NYSE:OPY – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Oppenheimer Trading ...

LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...